Posts Feed
Comments Feed

Halozyme Therapeutics Presents Pre-Clinical Studies On Dermal Remodeling With HTI-501, A Lysosomal Proteinase

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (”Matrix”), announced the presentation of new pre-clinical findings on the controlled modification of the Matrix with HTI-501 at the European Society for Dermatological Research (ESDR) and Japanese Society for Investigative Dermatology (JSID).

More: continued here

No Comments »

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.

1